Skip to main content
. 2021 Jul 31;26(15):4658. doi: 10.3390/molecules26154658

Scheme 1.

Scheme 1

CD38-targeting DFMT system depicted using DARA-MORF1 as the bispecific engager and HSA-(MORF2)y as the crosslinking effector molecule. DFMT is a two-step process involving step (1): specific antigen engagement by the bispecific engager followed by step (2): receptor crosslinking via the effector nanoconjugate. Crosslinking occurs via hybridization of complementary morpholino oligonucleotides conjugated to the bispecific engager and effector molecules.